Skip to main content
Back to all tickers

PDS Biotechnology Corporation (PDSB) stock forecast & analysis

0.9241

NasdaqCM · USDDelayed by 15 minutes

Up: +0.0515, +5.9%

0.9140Down: -0.0101, -1.1%

6 analyses

Use Arrow keys to explore price history; Home and End jump to the oldest and newest points
Price history for PDSB.US from 2026-05-18 to 2026-11-16 with 6 analysis runs marked; public runs are shown as stance-colored dots (Bullish, Bearish, or Neutral) and gated runs as a lock icon (sign in to read). Each marker is a link to sign in.BullishBearishNeutralLocked · sign in to read

Latest analysis: · verdict locked

Open
0.8087
Previous close
0.8726
Day range
0.8087 – 0.9685
52-week range
0.1950 – 1.79
Volume (shares)
5.25M
Net assets
Not available
Expense ratio
Not available
Shares outstanding
122.70M
P/E ratio
Not available
Dividend yield
0.00%
Beta
1.13
Market cap
113.39M
Market Scanner’s AI analysis of PDS Biotechnology Corporation (PDSB), updated November 2026: NantWorks investment and clinical trial progress for PDSB contrasted with persistent net losses and negative shareholder equity.

This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of PDS Biotechnology Corporation (PDSB) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.

Summary

NantWorks investment and clinical trial progress for PDSB contrasted with persistent net losses and negative shareholder equity.

Recent analyses for PDSB covered significant financing events, including NantWorks exercising warrants and closing private rounds totaling over $40 million, alongside strategic board appointments. The company's clinical development for PDS0301 in metastatic colorectal cancer and publication of Phase 2 results for PDS0101 were also noted. However, these developments were juxtaposed with consistent net losses, deteriorating asset values, and negative shareholder equity across multiple reporting periods.

PDSB news & sentiment

News reports highlighted positive developments including warrant exercises, private financing rounds, and strategic board appointments, alongside a "Buy" upgrade and a "Golden Cross" technical signal. However, other reports noted downward fair value revisions citing financing scrutiny and persistent net losses and negative shareholder equity.

PDSB technical picture

Price action showed significant upward momentum in some periods, with prices trading well above short- and long-term moving averages. Momentum indicators such as RSI and MFI indicated overbought conditions at times, while MACD readings varied. Support and resistance levels were defined by Bollinger Bands, with price action generally staying within these bands.

Fundamentals

The company has consistently reported net losses and negative operating cash flow across multiple periods, alongside a decline in total assets and shareholder equity. Valuation metrics such as Forward PE and ROE TTM indicate significant unprofitability relative to shareholder equity.

Factors discussed — upside

  • NantWorks exercising warrants, injecting approximately $3.9 million.
  • Successful closing of private financing rounds, securing up to $22.3 million and $22.6 million.
  • Appointment of Dr. Patrick Soon-Shiong to the Board of Directors.
  • Publication of Phase 2 clinical trial results for PDS0101 in JAMA Oncology.
  • Technical indicators showing strong bullish trends and upward momentum in some periods, with prices outperforming moving averages.

Factors discussed — risks

  • Consistent net losses reported across multiple fiscal years and quarters.
  • Deteriorating asset values and increasing liabilities in recent quarters.
  • Negative total shareholder equity as of June 30, 2026.
  • Operating cash flow has been negative for the past four reported years.
  • Some technical indicators showing the stock in overbought territory or diverging from price action.
  • Financing and Investment
  • Clinical Development
  • Financial Performance
  • Technical Analysis

Summary updated .

PDSB technical indicators

Common technical indicators for PDSB, computed from its daily closing prices.

IndicatorValueReading
50-day simple moving average1.00Price below
10-day exponential moving average1.06Price below
Relative strength index (14-day)42.57Neutral
MACD line (12/26/9)-0.0240Below its signal line
Bollinger bands (20-day, 2σ)0.79 – 1.58Price inside the bands

PDSB stock forecast — AI outlook

The most recent historical sample analysis of PDSB recorded this AI decision distribution. Newer analyses are locked — get the current verdict.

Buy 65%Hold 15%Sell 20%

As of

Analyses

Historical, AI-generated samples of past PDSB.US analyses — one per day, shown for context, not current guidance. Newer reports are locked; sign in to read them or generate a fresh one.

CaseDescriptionDate
  • Neutral

    PDS Biotechnology secured significant equity financing, which was accompanied by a recent surge in share price, though longer-term market trends show a notable downtrend. The company is prioritizing specific drug candidates and reported consistent net losses and negative operating income in its recent financial statements.

    Sign in to open the full 2026-09-09 PDSB.US analysis

  • Neutral

    PDS Biotechnology Corporation has secured significant equity financing and appointed a notable board member, which has seen its stock rise. However, the company continues to report net losses and its stock is trading below key moving averages, indicating a strong downtrend despite some positive short-term indicators.

    Sign in to open the full 2026-09-15 PDSB.US analysis

  • Neutral

    Technical indicators show strong short-term upward momentum with high buying pressure, though the stock remains below its long-term moving average and is in overbought territory. Fundamentally, the company has consistently reported net losses and declining shareholder equity.

    Sign in to open the full 2026-09-16 PDSB.US analysis

  • Neutral

    PDSB shows strong recent price momentum with significant gains and trading above key moving averages, though indicators suggest overbought conditions. However, the company's financials reveal a strained position with negative shareholder equity and consistent losses, despite recent positive news regarding financing and sector performance.

    Sign in to open the full 2026-09-17 PDSB.US analysis

  • Bullish

    PDS Biotech has announced positive clinical trial results and secured financing, alongside a strong bullish stock trend indicated by significant outperformance of moving averages and rapid price increases. Despite ongoing net losses and a highly unprofitable ROE, the company is strategically refocusing on specific cancer treatments.

    Sign in to open the full 2026-10-06 PDSB.US analysis

  • Locked

Frequently asked questions

What is the bull case for PDS Biotechnology Corporation?
Recent analyses highlighted significant financial injections from NantWorks exercising warrants and private financing rounds, alongside strategic board appointments and positive clinical trial developments for PDS0101 and PDS0301. Technical indicators in some periods also suggested strong bullish trends and upward momentum.
What are the risks for PDS Biotechnology Corporation?
The company has consistently reported net losses and negative shareholder equity, with deteriorating asset values and increasing liabilities noted. Operating cash flow has also been negative across multiple years, and some technical indicators have shown the stock in overbought territory or exhibiting divergence.
Is PDS Biotechnology Corporation bullish or bearish?
Recent AI analyses of PDS Biotechnology Corporation examined factors on both sides. Discussed upside: Recent analyses highlighted significant financial injections from NantWorks exercising warrants and private financing rounds, alongside strategic board appointments and positive clinical trial developments for PDS0101 and PDS0301. Technical indicators in some periods also suggested strong bullish trends and upward momentum. Discussed risks: The company has consistently reported net losses and negative shareholder equity, with deteriorating asset values and increasing liabilities noted. Operating cash flow has also been negative across multiple years, and some technical indicators have shown the stock in overbought territory or exhibiting divergence. These are descriptive observations, not a recommendation.
What is the latest sentiment on PDS Biotechnology Corporation?
News reports highlighted positive developments including warrant exercises, private financing rounds, and strategic board appointments, alongside a "Buy" upgrade and a "Golden Cross" technical signal. However, other reports noted downward fair value revisions citing financing scrutiny and persistent net losses and negative shareholder equity.
What is the PDS Biotechnology Corporation (PDSB) stock forecast?
Market Scanner publishes historical AI analysis samples rather than a live forecast. The most recent sample for PDS Biotechnology Corporation (PDSB), dated 2026-10-06, recorded an AI decision distribution of Buy 65%, Hold 15%, and Sell 20%. It is a dated historical sample shown for context, not current guidance.
What is the PDS Biotechnology Corporation (PDSB) stock prediction for 2026?
Market Scanner does not make price predictions for 2026. As of 2026-10-06, its most recent historical sample analysis of PDS Biotechnology Corporation (PDSB) recorded an AI decision distribution of Buy 65%, Hold 15%, and Sell 20%. Newer analyses are available after sign-in.
How does Market Scanner analyse PDS Biotechnology Corporation?
Every analysis of PDS Biotechnology Corporation runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for PDS Biotechnology Corporation?

Recent analyses highlighted significant financial injections from NantWorks exercising warrants and private financing rounds, alongside strategic board appointments and positive clinical trial developments for PDS0101 and PDS0301. Technical indicators in some periods also suggested strong bullish trends and upward momentum.

What are the risks for PDS Biotechnology Corporation?

The company has consistently reported net losses and negative shareholder equity, with deteriorating asset values and increasing liabilities noted. Operating cash flow has also been negative across multiple years, and some technical indicators have shown the stock in overbought territory or exhibiting divergence.

Is PDS Biotechnology Corporation bullish or bearish?

Recent AI analyses of PDS Biotechnology Corporation examined factors on both sides. Discussed upside: Recent analyses highlighted significant financial injections from NantWorks exercising warrants and private financing rounds, alongside strategic board appointments and positive clinical trial developments for PDS0101 and PDS0301. Technical indicators in some periods also suggested strong bullish trends and upward momentum. Discussed risks: The company has consistently reported net losses and negative shareholder equity, with deteriorating asset values and increasing liabilities noted. Operating cash flow has also been negative across multiple years, and some technical indicators have shown the stock in overbought territory or exhibiting divergence. These are descriptive observations, not a recommendation.

What is the latest sentiment on PDS Biotechnology Corporation?

News reports highlighted positive developments including warrant exercises, private financing rounds, and strategic board appointments, alongside a "Buy" upgrade and a "Golden Cross" technical signal. However, other reports noted downward fair value revisions citing financing scrutiny and persistent net losses and negative shareholder equity.

What is the PDS Biotechnology Corporation (PDSB) stock forecast?

Market Scanner publishes historical AI analysis samples rather than a live forecast. The most recent sample for PDS Biotechnology Corporation (PDSB), dated 2026-10-06, recorded an AI decision distribution of Buy 65%, Hold 15%, and Sell 20%. It is a dated historical sample shown for context, not current guidance.

What is the PDS Biotechnology Corporation (PDSB) stock prediction for 2026?

Market Scanner does not make price predictions for 2026. As of 2026-10-06, its most recent historical sample analysis of PDS Biotechnology Corporation (PDSB) recorded an AI decision distribution of Buy 65%, Hold 15%, and Sell 20%. Newer analyses are available after sign-in.

How does Market Scanner analyse PDS Biotechnology Corporation?

Every analysis of PDS Biotechnology Corporation runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.

Read the methodology

Bundles used
gemini-low-v2

Run a fresh PDSB.US analysis

Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.

Or read 6 earlier reports



Most analyzed tickers